Other languages IN8bio, Inc.

Equities

INAB

US45674E1091

Market Closed - Nasdaq Other stock markets 01:30:00 21/06/2024 am IST			5-day change	1st Jan Change
0.9202 ^USD	-7.98%		-45.23%	-33.32%

14/06	JonesTrading Adjusts IN8bio's Price Target to $6.50 From $5, Keeps Buy Rating	MT
13/06	IN8bio, Inc. Presents Positive Data Demonstrating Durable 1-Year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IN8bio, Inc. Presents Positive Data Demonstrating Durable 1-Year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100	14/06
IN8bio, Inc. Presents Progression-Free Survival Update from Phase 1 Study of INB-200 At 2024 American Society of Clinical Oncology Annual Meeting	03/06
IN8bio Plans to Report Improvement in Progression-Free Survival of Newly Diagnosed Patients With Glioblastoma Multiforme	24/05
In8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation At Asgct 2024	13/05
IN8bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma	30/04
Top Premarket Gainers	10/04
IN8bio, Inc. Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024	10/04
IN8bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03
IN8bio, Inc. to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024	06/03
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology	14/02
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%	12/12
Top Premarket Gainers	12/12
IN8bio, Inc. Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia	12/12
IN8bio Prices $46.9 Million Private Placement; Shares Surge 19%	11/12
IN8bio, Inc. Appoints Corinne Epperly to the Board of Directors	07/12
IN8bio, Inc.?s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma	20/11
IN8bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11
IN8bio, Inc. Presents Biologic Correlative Data from the Inb-200 Phase 1 Trial in Newly Diagnosed Glioblastoma At the Society for Immunotherapy of Cancer's 38Th Annual Meeting	06/11
IN8bio, Inc. Presents Positive Data Update from Induced Pluripotent Stem Cell Platform at the Society for Immunotherapy of Cancer 38th Annual Meeting	03/11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages IN8bio, Inc.

Equities

INAB

US45674E1091

Other languages

Filters